Esophageal cancer
Conditions
Interventions
1:Camrelizumab (SHR-1210)
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age: >= 18 years old, male or female; 2. Patients with esophageal cancer diagnosed by histopathology or cytology; 3. Have at least one measurable lesion (in accordance with RECIST 1.1); 4. ECOG score: 0-1 points; 5. Estimated survival period >= 3 months; 6. Subjects voluntarily joined the study, signed informed consent, good compliance, and follow-up; 7. Researchers believe that treatment can benefit.
Exclusion criteria
Exclusion criteria: 1. Those who have been confirmed to be allergic to the test drug and/or its excipients; 2. The subject has an immunodeficiency disease or a history of organ transplantation; 3. Pregnant or lactating women; 4. Patients who are not eligible for inclusion in this study are judged by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mPFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| mOS;ORR; | — |
Countries
China
Contacts
Public ContactSun Guoping
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed